Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 2/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | PTGES | O14684 | 5/20 | 0.54 |
| ▸ | ALOX5 | P09917 | 5/20 | 0.54 |
| ▸ | PPARG | P37231 | 5/20 | 0.54 |
| ▸ | CNR2 | P34972 | 1/20 | 0.51 |
| ▸ | CPA3 | P15088 | 3/20 | 0.50 |
| ▸ | CPA1 | P15085 | 2/20 | 0.49 |
| ▸ | CPB1 | P15086 | 1/20 | 0.49 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.49 |
| ▸ | PPARA | Q07869 | 1/20 | 0.48 |
| ▸ | MMP2 | P08253 | 5/20 | 0.48 |
| ▸ | MMP1 | P03956 | 2/20 | 0.48 |
| ▸ | MMP3 | P08254 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7300579 | 0.89 | FOLH1 (0.70) | FOLH1CYP1A2PTGESALOX5PPARG | |
| SCHEMBL5710051 | 0.89 | CYP1A2 (0.59) | FOLH1CYP1A2CPA3CPA1CPB1 | |
| SCHEMBL8728655 | 0.88 | FOLH1 (0.54) | FOLH1CYP1A2PTGESALOX5PPARG | |
| SCHEMBL27513375 | 0.88 | FOLH1 (0.68) | FOLH1CYP1A2PTGESALOX5PPARG | |
| SCHEMBL2948787 | 0.88 | FOLH1 (0.54) | FOLH1CYP1A2PTGESALOX5PPARG | |
| SCHEMBL2719254 | 0.86 | CA1 (0.55) | FOLH1CYP1A2PTGESALOX5PPARG | |
| SCHEMBL28588603 | 0.85 | CSNK1E (0.52) | FOLH1CNR2MMP2MMP1MMP3 | |
| SCHEMBL8733905 | 0.85 | MDM2 (0.54) | FOLH1CYP1A2PTGESALOX5PPARG | |
| SCHEMBL9068702 | 0.85 | FOLH1 (0.51) | FOLH1CYP1A2PTGESALOX5PPARG | |
| SCHEMBL28654947 | 0.85 | CA2 (0.56) | FOLH1CYP1A2PTGESALOX5PPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110402288-A | It is formed for pretreated higher-pressure region | SWEETWATER ENERGY INC | 2019-11-01 | — | — | CN | disclosed |
| EP-1005460-B1 | PROSTAGLANDIN ENDOPEROXIDE H SYNTHASE BIOSYNTHESIS INHIBITORS | ABBOTT LAB (US) | 2006-03-08 | — | — | EP | disclosed |
| US-20030105101-A1 | Prostaglandin endoperoxide H synthase biosynthesis inhibitors | BLACK LAWRENCE A (US) | 2003-06-05 | — | — | US | disclosed |
| US-6525053-B1 | 2-Benzyl-5-(4-methylsulfonylphenyl)-6-(4-fluorophenyl)-3(2H) -pyridazinone; cyclooxygenase (COX) inhibitors pain, fever, inflammation, rheumatoid arthritis, osteoarthritis; minimizes GI and renal side-effects | ABBOTT LABORATORIES | 2003-02-25 | — | — | US | disclosed |
| EP-1005460-A1 | PROSTAGLANDIN ENDOPEROXIDE H SYNTHASE BIOSYNTHESIS INHIBITORS | Abbott Laboratories (US) | 2000-06-07 | — | — | EP | disclosed |
| WO-1999010332-A1 | PROSTAGLANDIN ENDOPEROXIDE H SYNTHASE BIOSYNTHESIS INHIBITORS | ABBOTT LABORATORIES (US) | 1999-03-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030105101-A1 | Prostaglandin endoperoxide H synthase biosynthesis inhibitors | PTGIS, PTGES2, PTGS2 | FOLH1 1676/4885CYP1A2 28/4885PTGES 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.